Bibliography
- Parekh NR, Steiger E. Short bowel syndrome. Curr Treat Options Gastroenterol 2007;10(1):10-23
- American Gastroenterological Association Medical Position Statement. Short bowel syndrome and intestinal transplantation. Gastroenterology 2003;124:1105-10
- Nightingale J, Woodward JM. Small bowel and nutrition committee of the british society of gastroenterology. Guidelines for management of patients with a short bowel. Gut 2006;55(Suppl 4):iv1-12
- Misiakos EP, Macheras A, Kapetanakis T, Liakakos T. Short bowel syndrome: current medical and surgical trends. J Clin Gastroenterol 2007;41(1):5-18
- Jeppesen PB. Glucagon-like peptide-2: update of the recent clinical trials. Gastroenterology 2006;130(2 Suppl 1):S127-31
- Wales PW. Surgical therapy for short bowel syndrome. Pediatr Surg Int 2004;20(9):647-57
- Carbonnel F, Cosnes J, Chevret S, et al. The role of anatomic factors in nutritional autonomy after extensive small bowel resection. JPEN J Parenter Enteral Nutr 1996;20:275-80
- Doldi SB. Intestinal adaptation following jejuno-ileal bypass. Clin Nutr 1991;10:138-45
- Jeppesen PB, Mortensen PB. Intestinal failure defined by measurements of intestinal energy and wet weight absorption. Gut 2000;46:701-6
- Martin GR, Beck PL, Sigalet DL. Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation. World J Gastroenterol 2006;12(26):4117-29
- Yang H, Teitelbaum DH. Novel agents in the treatment of intestinal failure: humoral factors. Gastroenterology 2006;130(2 Suppl 1):S117-21
- Drozdowski L, Thomson AB. Intestinal mucosal adaptation. World J Gastroenterol 2006;12(29):4614-27
- Dubé PE, Brubaker PL. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 2007;293(2):E460-5
- Wallis K, Walters JR, Forbes A. Glucagon-like peptide 2 – current applications and future directions. Aliment Pharmacol Ther 2007;25(4):365-72
- Yusta B, Huang L, Munroe D, et al. Enteroendocrine localization of GLP-2 receptor expression. Gastroenterology 2000;119:744-55
- Irwin DM. Molecular evolution of proglucagon. Regul Pept 2001;98:1-12
- Hartmann B, Thulesen J, Kissow H, et al. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology 2000;141:4013-20
- Drucker DJ, Shi Q, Crivici A, et al. Regulation of the biological activity of glucagon-like peptide 2 by dipeptidyl peptidase IV. Natl Biotechnol 1997;15:673-7
- Ghatei MA, Goodlad RA, Taheri S, et al. Proglucagon-derived peptides in intestinal epithelial proliferation: glucagon-like peptide-2 is a major mediator of intestinal epithelial proliferation in rats. Dig Dis Sci 2001;46:1255-63
- Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996;93:7911-6
- Wojdemann M, Wettergren A, Hartmann B, et al. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J Clin Endocrinol Metab 1999;84:2513-7
- Munroe DG, Gupta AK, Kooshesh F, et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 1999;96:1569-73
- Lovshin J, Estall J, Yusta B, et al. Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling. J Biol Chem 2001;276(24):21489
- Bulut K, Pennartz C, Felderbauer P, et al. Glucagon like peptide-2 induces intestinal restitution through VEGF release from subepithelial myofibroblasts. Eur J Pharmacol 2008;578(2-3):279-85
- Hartmann B, Harr MB, Jeppesen PB, et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 2000;85:2884-8
- DaCambra MP, Yutsa B, Sumner-Smith M, et al. Structural determinants for activity of glucagon-like peptide-2. Biochemistry 2000;39:8888-94
- Tavares W, Drucker DJ, Brubaker PL. Enzymatic- and renal-dependent catabolism of the intestinotrophic hormone glucagon-like peptide-2 in rats. Am J Physiol Endocrinol Metab 2000;278:E134-9
- Sigalet DL. ALX-0600 (NPS Allelix Corp). Curr Opin Investig Drugs 2001;2(4):505-9
- Ferrone M, Scolapio JS. Teduglutide for the treatment of short bowel syndrome. Ann Pharmacother 2006;40(6):1105-9
- Metcalfe AJ, Oliver SD, Dietrich J. An evaluation of single dose administration of ALX-0600, a GLP-2 analog, in healthy male subjects [abstract 4973]. Gastroenterology 2000;118(4 Suppl 2 pt 2):A1072
- Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005;54:1224-31
- NPS Pharmaceutical News Release. October 11, 2007. Available from: http://www.npsp.com/news/news.php [Last accessed 10 February 2008]